The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Extended lab space for product development, customer demos, and training
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Subscribe To Our Newsletter & Stay Updated
